Come to see MILabs’ latest advancements in synergistic translational PET-SPECT-Optical-CT imaging. Check out this video for a sneak preview of MILabs’ latest products. To discuss your imaging needs, please contact us to schedule a meeting.
Selected recent scientific publications
The PSMA–targeted radiohybrid (rh) ligand with the best pharmacokinetics for 177Lu-radioligand therapy was identified using MILabs VECTor SPECT-PET-CT. [177Lu]Lu-rhPSMA-10.1 demonstrated favorable pharmacokinetics in mice. Clinical tests are needed to see if high tumor uptake and low uptake in nontarget tissues apply also in patients. Published in J. Nucl. Med., Oct. 2022, DOI: https://jnm.snmjournals.org/content/63/10/1489
Duke-NUS introduced [18F]FDG as a non-invasive preclinical biomarker for ZIKA disease evaluated in mice using VECTorCT technology by MILabs. [18F]FDG spleen uptake was found as a useful surrogate for interrogation of in situ tissue viral burden and inflammatory status. Published in the EJNMMI, Jul. 2022, DOI: https://pubmed.ncbi.nlm.nih.gov/35876869/
Join our team: open vacancies
MILabs seeks talented individuals to further scale up its organization.